Kazia Therapeutics Limited ADR (KZIA)
NASDAQ: KZIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:15 PM ET
KZIA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $101.70M
- EPS (TTM)
- -$6.85
- Dividend yield
- None
- 52-week range
- 4.86 – 17.40
- Day range
- 8.75 – 9.08
- Volume / Avg
- 61.74K / 262.41K
- Beta
- —
- Shares outstanding
- 11.43M
52-week range
KZIA stock today
Kazia Therapeutics (KZIA) is trading at $8.90 on Oct 9, up 0.91% (+$0.08), versus the S&P 500's 0.60% gain. Shares are 48.9% below their 52-week high of $17.40, set on Dec 8, 2025 and 83.1% above the 52-week low of $4.86, in the middle of the past year's range. KZIA is up 28.0% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 23.2%.
Kazia Therapeutics has posted a net loss over the last twelve months (EPS of -$6.85), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kazia Therapeutics
Company profileKazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. John Edwin Friend II, M.D.
- Headquarters
- Sydney, NSW
- Employees
- 6
- Website
- kaziatherapeutics.com
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$28.26+217.53%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Kazia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANIXAnixa Biosciences Inc. | 2.89 | -0.69% | $100.47M | vs KZIA |
| BMEABiomea Fusion Inc. | 1.42 | +3.28% | $102.30M | vs KZIA |
| PLYXPolaryx Therapeutics Inc. | 1.98 | -1.00% | $98.70M | vs KZIA |
| AARDAardvark Therapeutics Inc. | 4.72 | +0.21% | $103.30M | vs KZIA |
| OKUROnKure Therapeutics Inc. Class A | 2.38 | +3.48% | $96.38M | vs KZIA |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 5.49 | +4.17% | $106.18M | vs KZIA |
| CPIXCumberland Pharmaceuticals Inc. | 7.11 | +1.86% | $106.53M | vs KZIA |
| MISTMilestone Pharmaceuticals Inc. | 0.7567 | +6.26% | $94.21M | vs KZIA |
Indexes, lists and sector
Kazia Therapeutics stock FAQ
What is Kazia Therapeutics's stock price today?
KZIA last traded at $8.90 as of Oct 9, 2:15 PM EDT, up 0.91% on the day. Prices are delayed at least 15 minutes.
Does Kazia Therapeutics pay a dividend?
No. Kazia Therapeutics does not currently pay a regular cash dividend.
Who is Kazia Therapeutics's CEO?
Dr. John Edwin Friend II, M.D. is the chief executive officer of Kazia Therapeutics Limited ADR, which has about 6 employees.
Has KZIA ever split its stock?
Yes. The most recent KZIA stock split was a 1-for-5 split on Apr 17, 2025, one of 5 splits on record.
What is the KZIA 52-week high?
The 52-week high for KZIA is $17.40 and the 52-week low is $4.86. The stock is currently 48.9% below its high.